Massimiliano BONIFACIO

University of Verona

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

daniela cilloni

PROFESSOR

University of Turin

ITALY

View details

Antonio Cuneo

University of Ferrara

ITALY

View details

Valerio De Stefano

ITALY

View details

Giuseppe Alberto Maria PALUMBO

Associate Professor of Hematology

Università degli Studi di Napoli Federico II

ITALY

View details

Florian Heidel

Professor, Director

Universitätsmedizin Greifswald

GERMANY

View details

maria ilaria del principe

UNIVERSITY TOR VERGATA

ITALY

View details

Paola Guglielmelli

Associate professor

Università degli Studi di Napoli Federico II

ITALY

View details

Giovanni Caocci

University of Cagliari

ITALY

View details

vamsi kota

Augusta University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Massimiliano BONIFACIO

Research Interests

Explore related searches

Contact this professor

Articles (10)

Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib

Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement

Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus

Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements

Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”

Collaborators (9)

daniela cilloni

Antonio Cuneo

Valerio De Stefano

Giuseppe Alberto Maria PALUMBO

Florian Heidel

maria ilaria del principe

Paola Guglielmelli

Giovanni Caocci

vamsi kota

Make your next move.